financetom
Business
financetom
/
Business
/
Don't Expect Higher Bid for Canadian Western Bank, Raymond James Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Don't Expect Higher Bid for Canadian Western Bank, Raymond James Says
Jun 13, 2024 8:00 AM

10:42 AM EDT, 06/13/2024 (MT Newswires) -- Investors should not expect a higher bid for Canadian Western Bank ( CWESF ) than National Bank of Canada's ( NTIOF ) $5 Billion, or $52.24 per share, Raymond James said.

CWB's announcement that it has agreed to be acquired by NA was probably a surprise to the street, analyst Stephen Boland said in a note to clients.

"We believe similar to other bank acquisitions, National will need OSFI and Minister approval among others," Boland said.

"Hostile regulated financial services transactions are very rare in Canada, so we do not believe a superior bid would be expected (or approved) from the Big 5," the analyst said.

Boland maintained an Outperform rating on CWB and raised his price target to $52 from $37, which the analyst said is near the offer price and where he expects the stock to approach.

"National expects to realize material expense synergies over the next several years through the combination of certain platforms and funding," Boland said.

"What was not specifically stated (but may be included) was the benefit of moving CWB's loan book onto National's AIRB platform which it utilizes for most of its portfolios," the analyst said. "This is a substantial benefit that also maybe part of the rationale for the healthy premium knowing a material amount of risk-weighted assets can be released once that conversion occurs."

Boland said there could be western-based institutions (and politicians) in the middle of a Federal election (pre-election) that may not be overly positive on their "domestic bank" being acquired.

Price: 41.40, Change: -0.49, Percent Change: -1.17

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MBX Biosciences raises $163.2 mln in US IPO
MBX Biosciences raises $163.2 mln in US IPO
Sep 13, 2024
Sept 12 (Reuters) - MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial public offering. The biotechnology company priced its offering of 10.2 million shares at $16 apiece, at the high-end of its targeted range of $14 to $16 each....
FAA administrator to testify before Senate panel on Boeing oversight
FAA administrator to testify before Senate panel on Boeing oversight
Sep 13, 2024
WASHINGTON, Sept 12 (Reuters) - The head of the Federal Aviation Administration will testify on Sept. 25 before the Senate Permanent Subcommittee on Investigations on the planemaker's oversight of Boeing ( BA ), a committee aide told Reuters. The committee, led by Senator Richard Blumenthal, in June sharply questioned then Boeing ( BA ) CEO Dave Calhoun on the planemaker's...
BRIEF-Mbx Biosciences Prices Its IPO Of 10.2 Mln Shares At $16.00 Per Share
BRIEF-Mbx Biosciences Prices Its IPO Of 10.2 Mln Shares At $16.00 Per Share
Sep 13, 2024
Sept 12 (Reuters) - * MBX BIOSCIENCES ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING * MBX BIOSCIENCES - PRICING OF ITS IPO OF 10,200,000 SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $16.00 PER SHARE Source text for Eikon: ...
US FDA approves injectable version of Roche's multiple sclerosis therapy
US FDA approves injectable version of Roche's multiple sclerosis therapy
Sep 13, 2024
Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple sclerosis. (Reporting by Urvi Dugar; Editing by Subhranshu Sahu) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved